Revvity, Inc. (RVTY)
| Market Cap | 15.64B +62.6% |
| Revenue (ttm) | 2.91B +4.1% |
| Net Income | 237.55M -16.7% |
| EPS | 2.09 -11.5% |
| Shares Out | 111.59M |
| PE Ratio | 66.98 |
| Forward PE | 24.78 |
| Dividend | $0.28 (0.20%) |
| Ex-Dividend Date | Oct 23, 2026 |
| Volume | 3,693,791 |
| Open | 128.67 |
| Previous Close | 128.49 |
| Day's Range | 128.67 - 140.22 |
| 52-Week Range | 81.22 - 140.22 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 126.12 (-10.04%) |
| Earnings Date | Oct 26, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $126.12, which is a decrease of -10.04% from the latest price.
News
Revvity Transcript: 2026 Global Healthcare Conference
The company reported strong Q2 results, driven by diagnostics and a recovering life sciences segment, with significant backlog in high-content screening instruments and robust growth in China. Software innovation and AI integration are accelerating, while operational improvements and strategic acquisitions position the business for future organic growth.
Revvity Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The business has transformed into an innovation-focused life sciences and diagnostics leader, with strong recurring revenue, improved margins, and a robust growth outlook. AI integration and the Signals software platform are key differentiators, while disciplined capital allocation and portfolio management support long-term value.
Revvity Transcript: Wells Fargo 21st Annual Healthcare Conference
A tuck-in acquisition strengthens the reagents portfolio, while AI-driven demand is accelerating growth in high-content screening and software. Diagnostics and reproductive health segments remain robust, and margin guidance has been raised on strong execution. SaaS transition and new AI-based products are set to drive future growth.
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company sp...
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9...
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-qualit...
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Medical equipment maker Revvity raised its annual profit and revenue forecasts on Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-developm...
Revvity Earnings Call Transcript: Q2 2026
Q2 2026 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong Diagnostics and AI-related demand in Life Sciences. Full-year outlook was raised for organic growth, margins, and EPS, with robust cash flow and a pending China Immunodiagnostics divestiture.
Revvity Slides: Q2 2026
Revvity has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Revvity Earnings release: Q2 2026
Revvity released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Revvity Quarterly report: Q2 2026
Revvity has published its Q2 2026 quarterly earnings report on August 4, 2026.
Revvity Announces Financial Results for the Second Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing op...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Novem...
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages ...
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies a...
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performan...
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company...
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling ...
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabili...
Revvity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Diagnostics and life sciences segments delivered strong growth, with reproductive health and immunodiagnostics outperforming expectations. Strategic divestiture of China immunodiagnostics will support share buybacks and targeted acquisitions. Major software launches and AI integration, along with margin expansion and robust execution, position the company for continued growth.
Revvity Transcript: Bank of America Global Healthcare Conference 2026
Strong quarterly results were highlighted by the strategic divestiture of the China immunodiagnostics business, improving growth and margins. Life sciences and software segments showed positive momentum, with new AI-driven products and major software launches expected to drive future growth.
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for ...
Revvity Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong organic growth and margin outperformance, with robust innovation and a strategic China immunodiagnostics divestiture set to enhance growth and margins. Updated 2026 guidance reflects higher margins, focused capital allocation, and continued operational efficiency.
Revvity Earnings release: Q1 2026
Revvity released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Revvity Slides: Q1 2026
Revvity has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.